Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of NNC9204-1177 in overweight or obese men
NCT02941042Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2016
- Primary completion
- Sep 2017
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity and Overweight comparing NNC9204-1177 with Placebo (2 arms). Primary endpoint: Treatment Emergent Adverse Events. Started Oct 2016; status: completed.
02
Drugs
NN1177
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT02941042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02941042.